BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 26031595)

  • 1. Treatment of acute antibody-mediated rejection using bortezomib: a case report.
    Sin YH; Kim YJ; Oh JS; Lee JH; Kim SM; Kim JK
    Nephrology (Carlton); 2015 Jul; 20 Suppl 2():86-9. PubMed ID: 26031595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Banff Component Scoring-based Histologic Assessment of Bortezomib-based Antibody-mediated Rejection Therapy.
    Sadaka B; Ejaz NS; Shields AR; Cardi MA; Wadih G; Witte D; Abu Jawdeh BG; Alloway RR; Woodle ES
    Transplantation; 2015 Aug; 99(8):1691-9. PubMed ID: 25803498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Probable C4d-negative accelerated acute antibody-mediated rejection due to non-HLA antibodies.
    Niikura T; Yamamoto I; Nakada Y; Kamejima S; Katsumata H; Yamakawa T; Furuya M; Mafune A; Kobayashi A; Tanno Y; Miki J; Yamada H; Ohkido I; Tsuboi N; Yamamoto H; Yokoo T
    Nephrology (Carlton); 2015 Jul; 20 Suppl 2():75-8. PubMed ID: 26031592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A refractory case of subclinical antibody-mediated rejection due to anti-HLA-DQ antibody in a kidney transplant patient.
    Fujimoto T; Nakada Y; Yamamoto I; Kobayashi A; Tanno Y; Yamada H; Miki J; Ohkido I; Tsuboi N; Yamamoto H; Yokoo T
    Nephrology (Carlton); 2015 Jul; 20 Suppl 2():81-5. PubMed ID: 26031594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute T cell-mediated rejection accompanied by C4d-negative acute antibody-mediated rejection and cell debris in tubulus: A case report.
    Takamura T; Yamamoto I; Nakada Y; Katsumata H; Yamakawa T; Furuya M; Mafune A; Kobayashi A; Tanno Y; Miki J; Ohkido I; Tsuboi N; Yamamoto H; Yokoo T
    Nephrology (Carlton); 2015 Jul; 20 Suppl 2():70-4. PubMed ID: 26031591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib-based treatment of acute antibody-mediated rejection: a case report.
    Wang Q; Li XL; Xu XG; Shi BY; Zhang ZM; Li ZL; Han Y; Zhou WQ; Chen CQ; Cai M; Zhang X
    Genet Mol Res; 2015 Dec; 14(4):17951-8. PubMed ID: 26782441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib for refractory acute antibody-mediated rejection in kidney transplant recipients: A single-centre case series.
    De Sousa-Amorim E; Revuelta I; Diekmann F; Cofan F; Lozano M; Cid J; Palou E; Sole M; Campistol JM; Oppenheimer F
    Nephrology (Carlton); 2016 Aug; 21(8):700-4. PubMed ID: 26492594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of C4d staining as a humoral injury marker.
    Kara M; Demir F; Ata P; Ozel L; Gumrukcu G; Unal E; Canbakan M; Gucun M; Esadoglu V; Ozdemir E; Cemel H; Titiz MI
    Transplant Proc; 2012; 44(6):1694-6. PubMed ID: 22841245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Durable renal response after combination of bortezomib, corticosteroids, rituximab, and plasmapheresis for late antibody-mediated renal transplant rejection
.
    Ding Y; Francis J; Gautam A; Pelletier L; Sanchorawala V; Quillen K
    Clin Nephrol; 2018 Apr; 89(4):252-259. PubMed ID: 29208204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies.
    Gupta G; Abu Jawdeh BG; Racusen LC; Bhasin B; Arend LJ; Trollinger B; Kraus E; Rabb H; Zachary AA; Montgomery RA; Alachkar N
    Transplantation; 2014 Jun; 97(12):1240-6. PubMed ID: 24937198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of bortezomib as a rescue treatment for acute antibody-mediated rejection: report of three cases and review of literature.
    Tzvetanov I; Spaggiari M; Joseph J; Jeon H; Thielke J; Oberholzer J; Benedetti E
    Transplant Proc; 2012 Dec; 44(10):2971-5. PubMed ID: 23195008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection.
    Hardinger KL; Murillo D
    Clin Transpl; 2011; ():401-8. PubMed ID: 22755438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case of accelerated acute rejection after ABO-compatible living unrelated kidney transplantation.
    Matsuo N; Yamamoto H; Kobayashi A; Yamamoto I; Mitome J; Maruyama Y; Hayakawa H; Miyazaki Y; Utsunomiya Y; Hosoya T; Yamaguchi Y
    Clin Transplant; 2009 Aug; 23 Suppl 20():23-6. PubMed ID: 19594591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial.
    Eskandary F; Bond G; Schwaiger E; Kikic Z; Winzer C; Wahrmann M; Marinova L; Haslacher H; Regele H; Oberbauer R; Böhmig GA
    Trials; 2014 Apr; 15():107. PubMed ID: 24708575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.
    Walsh RC; Everly JJ; Brailey P; Rike AH; Arend LJ; Mogilishetty G; Govil A; Roy-Chaudhury P; Alloway RR; Woodle ES
    Transplantation; 2010 Feb; 89(3):277-84. PubMed ID: 20145517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case presentations on two patients who received bortezomib for antibody mediated rejection at BIDMC.
    Pavlakis M
    Clin Transpl; 2009; ():343-5. PubMed ID: 20524296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib for the treatment of chronic antibody-mediated kidney allograft rejection: a case report.
    Schwaiger E; Regele H; Wahrmann M; Werzowa J; Haidbauer B; Schmidt A; Böhmig GA
    Clin Transpl; 2010; ():391-6. PubMed ID: 21696056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-mediated rejection and treatment in pediatric patients: one center's experience.
    Gulleroglu K; Baskin E; Bayrakci US; Turan M; Ozdemir BH; Moray G; Karakayali H; Haberal M
    Exp Clin Transplant; 2013 Oct; 11(5):404-7. PubMed ID: 24128133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteasome inhibition with bortezomib: an effective therapy for severe antibody mediated rejection after renal transplantation.
    Sureshkumar KK; Hussain SM; Marcus RJ; Ko TY; Khan AS; Tom K; Vivas CA; Parris G; Jasnosz KM; Thai NL
    Clin Nephrol; 2012 Mar; 77(3):246-53. PubMed ID: 22377258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.